Skip to Content
Merck
All Photos(1)

Documents

11582950001

Roche

BM Chemiluminescence ELISA Substrate (POD)

Synonym(s):

ELISA substrate

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352204

form

solution

Quality Level

packaging

pkg of 250 mL (for 2500 wells or 1000 tubes)

manufacturer/tradename

Roche

storage condition

(Keep container tightly closed in a dry and well-ventilated place.)

technique(s)

ELISA: suitable

color

clear colorless

solubility

water: miscible

suitability

suitable for chemiluminescence

shipped in

wet ice

storage temp.

2-8°C

General description

The sensitivity of enzyme-linked immunosorbent assays often depends on the detection limit of the colorimetric substrates used. In addition, the dynamic range of a colorimetric assay is restricted to a maximum of two orders of magnitude due to the physical/chemical limitations of absorbance measurement (Law of Lambert & Beer). With chemiluminescence technology, a nonradioactive method, which combines the convenience of tube or microplate-based immunoassays with the advantages of isotopic assays, is now available. The BM Chemiluminescence ELISA Substrate (POD) has been evaluated with different immunoassays on the LB 96 P microplate reader and the LB 953 tube chemiluminescence analyzer from EG&G;Berthold.

Application

The BM Chemiluminescence ELISA Substrate (POD) provides a substrate solution for peroxidase-based (POD, HRP) secondary detection systems with highly sensitive, enhanced chemiluminescence. This reagent has been optimized for ELISA applications to be run on a microplate chemiluminescence reader (96-well format) or tube-format luminometers.

Features and Benefits

  • Improved sensitivity
  • Large dynamic range
  • Rapid and constant signal

Contents
Substrate Reagent A (buffered solution that contains luminol/4-iodophenol)
Starting Reagent B (buffered solution that contains a stabilized form of H2O2)

Principle

Horseradish peroxidase (POD, HRP), in the presence of hydrogen peroxide (H2O2), catalyzes the oxidation of diacylhydrazides such as luminol. A reaction product in an excited state is thus formed, then decays to the ground state by emitting light. Strong enhancement of the light emission is achieved by the agent 4-iodophenol (contained), which acts as a radical transmitter between the formed oxygen radical and luminol.

Preparation Note

Working solution: Preparation of working solution

The BM Chemiluminescence ELISA Substrate is supplied as a set of two stable solutions. Depending on the scale of the assay, the appropriate amount of substrate solution has to be prepared 15 minutes before use:
  • Add to 100 parts of solution A one part of solution B.
  • Stir the mixture for at least 15 minutes at 15 to 25 °C to equilibrate the components.
Premixed working solution stored at 2 to 8 °C should be warmed up to 15 to 25 °C to avoid temperature effects during measurement.
Storage conditions (working solution): The premixed solution is stable for 1 week, when stored at 2 to 8 °C.

Other Notes

For life science research only. Not for use in diagnostic procedures.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

does not flash

Flash Point(C)

does not flash


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Adam Zwolak et al.
Scientific reports, 12(1), 20538-20538 (2022-11-30)
TL1A (TNFSF15) is a TNF superfamily ligand which can bind the TNFRSF member death receptor 3 (DR3) on T cells and the soluble decoy receptor DcR3. Engagement of DR3 on CD4+ or CD8+ effector T cells by TL1A induces downstream signaling, leading
Stefania Kalogera et al.
Scientific reports, 11(1), 24285-24285 (2021-12-22)
Osteoarthritis (OA) and rheumatoid arthritis (RA) are serious and painful diseases. Protease-activated receptor 2 (PAR2) is involved in the pathology of both OA and RA including roles in synovial hyperplasia, cartilage destruction, osteophyogenesis and pain. PAR2 is activated via cleavage
Hayley Dingsdale et al.
Journal of psychiatric research, 150, 47-53 (2022-03-31)
Altered serum levels of brain-derived neurotrophic factor (BDNF) are consistently linked with neurological disorders. BDNF is also increasingly implicated in the pathogenesis of neurodevelopmental disorders, particularly those found more frequently in males. At birth, male infants naturally have significantly lower
Hyeseon Cho et al.
bioRxiv : the preprint server for biology (2021-04-07)
The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and therapeutic antibodies underscores the urgent need for new antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies
Arno R Bourgonje et al.
Alimentary pharmacology & therapeutics, 56(4), 675-693 (2022-06-07)
Increased collagen remodelling is a key pathophysiological component underlying intestinal stricture and fistula development in Crohn's disease (CD). To investigate associations between serological biomarkers of collagen turnover and disease behaviour according to the Montreal classification in patients with CD. Serological

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service